UroGen Pharma Ltd. (URGN) - Stock Analysis
Last updated: Mar 15, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
UroGen Pharma is trading on optimism ahead of an FDA decision for UGN-102, with the stock showing a steady rebound. A positive approval could drive rapid upside, but legal overhang and cash burn add risk. Near-term technical levels offer clear entry and stop points.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠High gross margin ⢠Severe cash burn ⢠Negative equity URGN exhibits strong product-level gross margins but is cash-burning and highly leveraged, with large operating losses and negative equity despite short-term liquidity.
Price Behavior
Key Price Behavior Insights: ⢠Below last-month mean ⢠RSI weak (highâ30s) ⢠Series of lower highs Support Level: $18.40 Resistance Level: $20.20; $22.30 URGN is in a shortâterm downtrend, trading below its lastâmonth average with RSI in the highâ30s, immediate support near $18.40 but resistance at ~$20.20 and stronger near $22.30, offering a defined rebound risk if support holds but risk of further downside if it fails.
Sentiment & News
Key News Insights: ⢠ZUSDURI launch ⢠Permanent Jâcode ⢠Liquidity boost UroGen reported improved Q4 results, initiated the ZUSDURI commercial launch with a permanent Jâcode and supportive clinical data, and refinanced debt to boost liquidity while withholding nearâterm ZUSDURI revenue guidance amid ongoing cashâburn risk.
AI Summary
URGN has shifted from a preâcommercial R&D story to a commercialâstage companyâpermanent Jâcode, early ZUSDURI sales and refinancing materially extend runwayâbut the investment thesis now rests on execution: achieving PEFâdose conversion under ~30 days and delivering consistent sequential quarterly ZUSDURI revenue growth to stem the ~â$162M operating cash burn. Monitor weekly doseâconversion metrics, quarterly revenue vs. SG&A trends, and cash runway versus the 8.25% debt service as the specific nearâterm triggers that will validate upside or force dilutive financing.
Description
UroGen Pharma Ltd. is a biotechnology company developing treatments for urothelial diseases and specialty cancers, using a biocompatible reverse thermal gel platform to modify drug delivery and exposure. Its pipeline includes UGN-102, currently in Phase III for several forms of non-muscle invasive urothelial cancer, and UGN-301 for high-grade disease, alongside a commercial offering based on its hydrogel technology. The company maintains licensing and development agreements with Allergan and Agenus and a research collaboration with MD Anderson, and is based in Princeton, New Jersey (incorporated 2004).
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jul 21 | Jul 28 | URGN | UroGen Pharma Ltd. | UroGen Pharma is trading on optimism ahead of an FDA decision for UGN-102, with the stock showing a steady rebound. A positive approval could drive rapid upside, but legal overhang and cash burn add risk. Near-term technical levels offer clear entry and stop points. | Closed | +22.3% |